FDA
-
-
-
-
-
-
-
Immix Biopharma to Participate in the Jefferies Global Healthcare Conference
-
-
-
-
-
-
-
Immix Biopharma completes $100 million stock offering
-
-
-
-
-
-
-
Immix Biopharma Appoints Chief Commercial Officer to Drive NXC-201 Launch
-
-
-
-
-
-
-
Immix Biopharma to Present at the 37th Annual Piper Sandler Healthcare Conference
-
-
-
-
-
-
-
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
-
-
-
-
-
-
-
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
-
-
-
-
-
-
-
Immix Biopharma Announces Positive Results for NXC-201 at ASCO Oral Presentation, Enabling Pathway to Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
-
322,996 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

